Form D · Biotechnology
CARGO Therapeutics, Inc.
San Mateo, CA · CIK 0001966494
Offering snapshot reported Mar 1, 2023 · SEC filing
- Reported sold
- $68.8M Offering amount: $201M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 9, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2023 | Initial | $68,832,003 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-474596
Source: Form D, filed Mar 1, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abraham Bassan | Director |
| Gina Chapman | Director, Executive |
| Cassandra Gianna Luca | Director |
| Heath Lukatch | Director |
| Crystal Mackall | Director |
| John Orwin | Director |
| Anup Radhakrishnan | Executive |
| Krishnan Viswanadhan | Director |
| Jeffrey Walsh | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1900 Alameda De Las Pulgas Suite 350
San Mateo, CA, 94403
San Mateo, CA, 94403